Sepsis Management In A Case Of Myasthenic Crisis: A Case Report
Abstract
Myasthenic crisis can affect the respiratory muscles in a life-limiting way that requires intubation and mechanical ventilation. This is a case report of a myasthenic crisis in a 61-year-old woman that became complicated following a lack of response to plasmapheresis, intravenous immunoglobulin (IVIG) therapy, and the development of septic shock. The co-occurrence of myasthenic crisis and sepsis is a challenging condition. Many antibiotics cause flare-ups of myasthenia gravis. Infection and sepsis can exacerbate myasthenia. We discuss the successful management of certain unique challenges. To treat sepsis, drugs that may cause deterioration of myasthenia gravis, such as amikacin, ciprofloxacin, colistin, vancomycin, amphotericin B, and voriconazole were prescribed, but eventually the sepsis was cured. After eradicating the infections and stabilizing the patient's hemodynamic, she received rituximab. After 3 weeks of treatment, she responded well to the rituximab, the respiratory failure recovered, and she was extubated and discharged from the ICU after 3 months of hospitalization. This report demonstrates that when the myasthenic patient is under mechanical ventilation, can use even cautionary drugs.
[2] Rousseff RTJJocm. Diagnosis of myasthenia gravis. 2021;10(8):1736.
[3] Payus AO, Hsiang JLW, Qian LJ, Ibrahim A, Raymond AAJTAjocr. Myasthenic crisis as the first presentation of myasthenia gravis: a case report. 2021;22: e928419-1.
[4] Sheikh S, Alvi U, Soliven B, Rezania KJJoCM. Drugs that induce or cause deterioration of myasthenia gravis: an update. 2021;10(7):1537.
[5] Dalakas MC, Meisel AJERoN. Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis. 2022;22(4):313-8.
[6] Ipe TS, Davis AR, Raval JSJFiN. Therapeutic plasma exchange in myasthenia gravis: a systematic literature review and meta-analysis of comparative evidence. 2021; 12:662856.
[7] Aydin Y, Ulas AB, Mutlu V, Colak A, Eroglu AJTEjom. Thymectomy in myasthenia gravis. 2017;49(1):48.
[8] Kassardjian C, Widdifield J, Paterson J, Kopp A, Nagamuthu C, Barnett C, et al. Serious infections in patients with myasthenia gravis: population‐based cohort study. 2020;27(4):702-8.
[9] Lemos E, de La Hoz F, Einarson T, McGhan W, Quevedo E, Castañeda C, et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. 2014;20(5):416-23.
[10] Nosheen N, Bushra J, Shahla S, Najeeha T, Fauzio A K, Rabia H. Mortality in sepsis and its relationship with gender. 2015.
[11] Argov ZJOToND. Drug-induced neuromuscular disorders. 2014:338.
[12] Rodrigues D, Baldissera GS, Mathos D, Sartori A, Zavascki AP, Rigatto MHJBJoM. Amikacin for the treatment of carbapenem-resistant Klebsiella pneumoniae infections: clinical efficacy and toxicity. 2021;52(4):1913-9.
[13] Gummi RR, Kukulka NA, Deroche CB, Govindarajan RJM, nerve. Factors associated with acute exacerbations of myasthenia gravis. 2019;60(6):693-9.
[14] Mohammadi M, Khayat H, Sayehmiri K, Soroush S, Sayehmiri F, Delfani S, et al. Synergistic effect of colistin and rifampin against multidrug resistant Acinetobacter baumannii: a systematic review and meta-analysis. 2017; 11:63.
[15] Karballaei-Mirzahosseini H, Kaveh-Ahangaran R, Shahrami B, Rouini MR, Najafi A, Ahmadi A, et al. Pharmacokinetic study of high-dose oral rifampicin in critically Ill patients with multidrug-resistant Acinetobacter baumannii infection. 2022;30(2):311-22.
[16] Mirzahosseini HK, Najmeddin F, Mojtahedzadeh MJAoPP. A Review Article on the Effectiveness of Rifampin in the Treatment of Staphylococcal Meningitis. 2020; 1:162.
[17] Nittoli T, Zumsteg AB, Bandyopadhyay A, Federici S, Coppi A, Jorgenson S, et al. Potent Rifampicin derivatives can clear MRSA infections at single low doses when concomitantly dosed with Vancomycin. 2023:1-9.
[18] Akcam FZ, Bacanak BN, Turk O, Yilmaz GR, Pekbay B, Yirmibes EOB, et al. A rare side effect due to voriconazole: myasthenia gravis. 2022;78(8):1357-9.
[19] Moran C, Grussemeyer CA, Spalding JR, Benjamin Jr DK, Reed SDJTPidj. Candida albicans and non-albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs. 2009;28(5):433.
[20] Li Z, Zhuang H, Wang G, Wang H, Dong YJBid. Prevalence, predictors, and mortality of bloodstream infections due to methicillin-resistant Staphylococcus aureus in patients with malignancy: systemic review and meta-analysis. 2021;21(1):1-10.
Files | ||
Issue | Article in Press | |
Section | Case Report(s) | |
Keywords | ||
Myasthenic Crisis Cautionary drugs Sepsis Multi Drugs Resistance |
Rights and permissions | |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |